600763 通策医疗
2025/06 - 中期
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入1,448,4402.68%2,873,7772,846,5082,718,6122,780,725
减:营业总成本1,060,9032.68%2,228,5652,200,0292,029,1511,873,083
    其中:营业成本858,2032.82%1,767,3061,749,7541,609,0251,500,000
               财务费用21,075-6.92%48,36049,58946,55323,020
               资产减值损失----155------
公允价值变动收益----1,417------
投资收益27,0919.73%46,42760,19338,30156,134
    其中:对联营企业和合营企业的投资收益21,14024.74%32,63634,80010,74812,396
营业利润421,1943.29%698,632711,888733,906974,891
利润总额419,9223.19%694,009708,824737,984974,584
减:所得税费用39,6200.59%121,878130,434122,306188,434
净利润380,3023.47%572,131578,390615,678786,150
减:非控股权益59,1442.38%70,70577,94967,40983,343
股东净利润321,1583.67%501,427500,441548,269702,807

市场价值指针
每股收益 (元) *0.7204.35%1.1201.1201.7102.190
每股派息 (元) *----0.4500.436----
每股净资产 (元) *9.279-24.75%9.00511.86710.3258.984
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容